Li Guangdi, Xu Ming, Yue Tingting, Gu Weijie, Tan Li
Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, China; Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha 410078, China.
Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha 410078, China.
Biochem Pharmacol. 2021 Mar;185:114485. doi: 10.1016/j.bcp.2021.114485. Epub 2021 Feb 20.
Since the 1950s, great efforts have been made to develop antiviral agents against many infectious diseases such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), human cytomegalovirus (HCMV), herpes simplex virus (HSV), and varicella-zoster virus (VZV). Among the list of nearly 106 antiviral agents approved in the past five decades, Prof. Erik De Clercq has contributed to the development of 7 antiviral drugs: tenofovir disoproxil fumarate (Viread®) for HIV and HBV treatment, tenofovir alafenamide (Vemlidy®) for HIV and HBV treatment, brivudine (Zostex®) for HSV-1 and VZV treatment, valacyclovir (Valtrex®) for HSV and VZV treatment, adefovir dipivoxil (Hepsera®) for HBV treatment, stavudine (Zerit®) for HIV treatment, and cidofovir (Vistide®) for treating HCMV retinitis in AIDS patients. In addition to the above antiviral drugs, his contributions include two anti-cancer drugs: rabacfosadine (Tanovea®-CA1) for canine lymphoma and plerixafor (Mozobil®) for multiple myeloma and non-Hodgkin's lymphoma. These achievements are driven by his life-long passions for antiviral research and successful collaborations worldwide. To honor the 80th birthday of Prof. Erik De Clercq, this study highlights his scientific achievements and the importance of life-long passions and collaborations in the success of antiviral research and drug development.
自20世纪50年代以来，人们为研发抗多种传染病的抗病毒药物付出了巨大努力，这些传染病包括人类免疫缺陷病毒（HIV）、乙型肝炎病毒（HBV）、丙型肝炎病毒（HCV）、人巨细胞病毒（HCMV）、单纯疱疹病毒（HSV）和水痘带状疱疹病毒（VZV）。在过去五十年中获批的近106种抗病毒药物中，埃里克·德·克勒克教授参与研发了7种抗病毒药物：用于治疗HIV和HBV的替诺福韦酯（Viread®）、用于治疗HIV和HBV的替诺福韦艾拉酚胺（Vemlidy®）、用于治疗HSV-1和VZV的溴夫定（Zostex®）、用于治疗HSV和VZV的伐昔洛韦（Valtrex®）、用于治疗HBV的阿德福韦酯（Hepsera®）、用于治疗HIV的司他夫定（Zerit®）以及用于治疗艾滋病患者巨细胞病毒性视网膜炎的西多福韦（Vistide®）。除了上述抗病毒药物外，他的贡献还包括两种抗癌药物：用于犬淋巴瘤的雷巴福沙定（Tanovea®-CA1）和用于多发性骨髓瘤及非霍奇金淋巴瘤的普乐沙福（Mozobil®）。这些成就源于他对抗病毒研究的毕生热情以及在全球范围内的成功合作。为庆祝埃里克·德·克勒克教授80岁生日，本研究重点介绍了他的科学成就，以及毕生热情和合作在抗病毒研究与药物开发成功中的重要性。
